SEC Form 4 · accession 0001179110-18-004708

Blueprint Medicines Corp · BPMC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Kate Haviland

Officer — Chief Business Officer

Period of report

Mar 16, 2018

Accepted (ET)

Mar 20, 2018 · 8:02 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001597264

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 16, 2018	M	1,571	$16.28	A	7,445	D
Common Stock	Mar 16, 2018	M	2,500	$36.05	A	9,945	D
Common Stock^F3	Mar 16, 2018	S	500	$102.19	D	9,445	D
Common Stock^F4	Mar 16, 2018	S	1,800	$101.32	D	7,645	D
Common Stock^F5	Mar 16, 2018	S	1,200	$100.02	D	6,445	D
Common Stock^F6	Mar 16, 2018	S	571	$99.20	D	5,874	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$16.28	Mar 16, 2018	M	1,571	D	—	Feb 1, 2026	Common Stock	1,571	120,639	D
Stock Option (Right to Buy)^F8	$36.05	Mar 16, 2018	M	2,500	D	—	Feb 16, 2027	Common Stock	2,500	118,139	D

Explanation of responses

F1The exercises reported on this Form 4 was effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 21, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.90 to $102.84 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.
F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.98 to $101.80 per share.
F5The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.66 to $100.54 per share.
F6The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.73 to $99.50 per share.
F7This option was granted on February 1, 2016. This option vested with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.
F8This option was granted on February 16, 2017. This option vested with respect to 1/48th of the shares underlying the option on March 16, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.